CN115298173A - 羟基吡咯烷衍生物及其医药用途 - Google Patents

羟基吡咯烷衍生物及其医药用途 Download PDF

Info

Publication number
CN115298173A
CN115298173A CN202180026438.5A CN202180026438A CN115298173A CN 115298173 A CN115298173 A CN 115298173A CN 202180026438 A CN202180026438 A CN 202180026438A CN 115298173 A CN115298173 A CN 115298173A
Authority
CN
China
Prior art keywords
group
substituted
carbon atoms
atom
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180026438.5A
Other languages
English (en)
Chinese (zh)
Inventor
山腰修平
石泽公平
萩原秀一
坂田光命
丹羽靖哉
田中实
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN115298173A publication Critical patent/CN115298173A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180026438.5A 2020-03-31 2021-03-30 羟基吡咯烷衍生物及其医药用途 Pending CN115298173A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-065410 2020-03-31
JP2020065410 2020-03-31
PCT/JP2021/013694 WO2021201036A1 (ja) 2020-03-31 2021-03-30 ヒドロキシピロリジン誘導体およびその医薬用途

Publications (1)

Publication Number Publication Date
CN115298173A true CN115298173A (zh) 2022-11-04

Family

ID=77927631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026438.5A Pending CN115298173A (zh) 2020-03-31 2021-03-30 羟基吡咯烷衍生物及其医药用途

Country Status (5)

Country Link
US (1) US20230312542A1 (https=)
EP (1) EP4129402A4 (https=)
JP (1) JP7684282B2 (https=)
CN (1) CN115298173A (https=)
WO (1) WO2021201036A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240327392A1 (en) * 2021-06-25 2024-10-03 Albius Sciences Alpha Private Limited Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections
KR20240148807A (ko) * 2022-03-22 2024-10-11 옵쉐스트바 스 아그라니첸너이아트볫스트벤너스찌유 "빅-즈다로비예쥐보트니흐" 메데토미딘 및 그 유도체의 제조 방법
CN119677735A (zh) * 2022-05-11 2025-03-21 基因泰克公司 作为vhl配体的苯并噻唑化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425288A1 (en) 2000-10-11 2002-05-02 Sander G. Mills Pyrrolidine modulators of ccr5 chemokine receptor activity
AU2006223482A1 (en) 2005-03-14 2006-09-21 Janssen Pharmaceutica, N.V. Process for the preparation of opioid modulators
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
PL2242759T3 (pl) 2008-02-06 2013-06-28 Astrazeneca Ab Związki
EP2384328B1 (en) 2008-11-27 2013-02-13 Boehringer Ingelheim International GmbH 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and process for preparing them
US8673954B2 (en) * 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
AU2010274001A1 (en) * 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
WO2011084402A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP2752410B1 (en) 2011-10-25 2016-08-31 Shionogi & Co., Ltd. Heterocycle derivative having pgd2 receptor antagonist activity
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US9783527B2 (en) 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
WO2019084026A1 (en) * 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
IL281188B2 (en) * 2018-09-07 2025-08-01 Arvinas Operations Inc Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

Also Published As

Publication number Publication date
EP4129402A4 (en) 2024-06-12
JPWO2021201036A1 (https=) 2021-10-07
EP4129402A1 (en) 2023-02-08
US20230312542A1 (en) 2023-10-05
JP7684282B2 (ja) 2025-05-27
WO2021201036A1 (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
CN113501821B (zh) 具有mgat-2抑制活性的稠合环衍生物
US7335670B2 (en) Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
JP6618120B2 (ja) ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EP1818326A1 (en) Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds
JP7684282B2 (ja) ヒドロキシピロリジン誘導体およびその医薬用途
JP2021522253A (ja) 化合物及びその使用
EP3766877A1 (en) Indole compound and pharmaceutical use thereof
CN106255679A (zh) 用作na v通道抑制剂的杂环化合物及其用途
CN102811998B (zh) 新的亲环素抑制剂及其用途
CA2897843A1 (en) Pyrazolopyrimidine compounds
JP7015092B2 (ja) ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
CA3140173A1 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
CA3140170A1 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
JP2023516102A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
WO2015089137A1 (en) Acylguanidines as tryptophan hydroxylase inhibitors
WO2025218831A2 (zh) 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用
WO2012038904A1 (fr) Derives de nicotinamide, leur preparation et leur application en therapeutique
CN101434570B (zh) 吡咯烷衍生物及其制备方法和应用
JP2019510053A (ja) シクロフィリンの阻害のための化合物及びその使用
CA2960432C (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation
JP2009523747A (ja) α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用
CN105936633B (zh) 5-（3-异丙基苯并异噁唑）吡嗪-2-胺及其制备方法
CN103626845A (zh) 作为糖原磷酸化酶抑制剂的芳基并吡咯-2-甲酰胺二肽衍生物、其制备方法及医药用途
JP2019127467A (ja) ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物を含有する医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination